Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: In vitro inhibition of ADAMTS13 activity by hemoglobin

Blood

Volumn 105, Issue 2, 2005, Pages 542-544

  Studt, Jan Dirk ^b   Kremer Hovinga, Johanna A ^b   Antoine, Gerhard ^b   Hermann, Martin ^b   Rieger, Manfred ^b   Scheiflinger, Friedrich ^b   Lämmle, Bernhard ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CASE REPORT; ENZYME INHIBITION; FATALITY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOGLOBULIN PRODUCTION; INTRAVASCULAR HEMOLYSIS; MALE; PLASMA TRANSFUSION; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 11244281582     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-06-2096     Document Type: Article

References (25)

1. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
2. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339:1585-1594.
4. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494.
5. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99:11902-11907.
6. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in 2 brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120:821-824.
7. Schneppenheim R, Budde U, Oyen F, et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003;101:1845-1850.
8. Assink K, Schiphorst R, Allford S, et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int. 2003;63:1995-1999.
9. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103:1305-1310.
10. Veyradier A, Lavergne JM, Ribba AS, et al. Ten candidate ADAMTS13 mutations in 6 French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost. 2004;2:424-429.
11. Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839-2846.
12. Scheiflinger F, Knöbl P, Trattner B, et al. Non-neutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241-3243.
13. Dong JF, Moake JL, Nolasco L, et al. ADAMTS13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100: 4033-4039.
14. Dong JF, Moake JL, Bernardo A, et al. ADAMTS13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639.
15. Studt JD, Kremer Hovinga JA, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly. 2003;133:325-332.
16. Studt JD, Böhm M, Budde U, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost. 2003;1:1882-1887.
17. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
18. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
19. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74:101-108.
20. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001;113:649-651.
21. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14:437-454.
22. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded VWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389.
23. Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol. 2002;81: 430-435.
24. Obert B, Tout H, Veyradier A, et al. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to VWF. Thromb Haemost. 1999;82:1382-1385.
25. Pimstone NR. Renal degradation of hemoglobin. Semin Hematol. 1972;9:31-42.